HUTCHMED CHINA-ADR(NASDAQ:HCM) stock News

HCM Latest News, Press Relases and Analysis

All

Press Releases

7 days ago - By: HUTCHMED (China) Limited

HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2025

7 days ago - By: HUTCHMED (China) Limited - Mentions: LSE -

HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2025

a month ago - By: Benzinga - Mentions: QMMM SERV FUN WBD ...

IBEX, Tesla, IonQ, Warner Bros. Discovery And Other Big Stocks Moving Higher On Friday

a month ago - By: HUTCHMED (China) Limited

Save the Date: HUTCHMED to Present R&D Updates on October 31, 2025

2 months ago - By: Zacks Investment Research - Mentions: MC CENX

Best Momentum Stock to Buy for August 19th

2 months ago - By: Benzinga - Mentions: GSAT PGY ADV REAL ...

Earnings Scheduled For August 7, 2025

a month ago - By: HUTCHMED (China) Limited - Mentions: LSE -

Save the Date: HUTCHMED to Present R&D Updates on October 31, 2025

a month ago - By: HUTCHMED (China) Limited

HUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer and the CSCO Annual Meeting 2025

a month ago - By: HUTCHMED (China) Limited - Mentions: LSE -

HUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer and the CSCO Annual Meeting 2025

2 months ago - By: HUTCHMED (China) Limited

HUTCHMED Announces Appointment of Acting Chief Executive Officer

2 months ago - By: HUTCHMED (China) Limited - Mentions: LSE -

HUTCHMED Announces Appointment of Acting Chief Executive Officer

2 months ago - By: HUTCHMED (China) Limited

HUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China

2 months ago - By: HUTCHMED (China) Limited - Mentions: LSE -

HUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China

2 months ago - By: HUTCHMED (China) Limited - Mentions: LSE -

HUTCHMED Reports 2025 Interim Results

3 months ago - By: HUTCHMED (China) Limited

HUTCHMED to Announce 2025 Half-Year Financial Results

3 months ago - By: HUTCHMED (China) Limited - Mentions: LSE -

HUTCHMED to Announce 2025 Half-Year Financial Results

3 months ago - By: HUTCHMED (China) Limited

HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor Therapy

3 months ago - By: HUTCHMED (China) Limited - Mentions: LSE -

HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor Therapy

4 months ago - By: Zacks Investment Research

Wall Street Analysts See a 68.3% Upside in HUTCHMED (HCM): Can the Stock Really Move This High?

4 months ago - By: Stocktwits - Mentions: LLY

Hutchmed Stock Hits Over One-Month High After China Accepts Kidney Cancer NDA Filed With Partner Innovent Biologics

4 months ago - By: HUTCHMED (China) Limited

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma

4 months ago - By: HUTCHMED (China) Limited - Mentions: LSE -

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma

4 months ago - By: HUTCHMED (China) Limited

HUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual Meeting

4 months ago - By: HUTCHMED (China) Limited - Mentions: LSE -

HUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual Meeting

5 months ago - By: HUTCHMED (China) Limited

HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting

5 months ago - By: HUTCHMED (China) Limited - Mentions: LSE -

HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting

5 months ago - By: Virtual Investor Conferences - Mentions: VIOT LSE - NYSE ...

Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing

5 months ago - By: Virtual Investor Conferences - Mentions: YRD IH BLTE VIOT ...

UPDATE - International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 15, 2025

5 months ago - By: Virtual Investor Conferences - Mentions: YRD IH BLTE VIOT ...

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 15, 2025

6 months ago - By: HUTCHMED (China) Limited

HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025

6 months ago - By: HUTCHMED (China) Limited - Mentions: LSE -

HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025

6 months ago - By: HUTCHMED (China) Limited

HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China

6 months ago - By: HUTCHMED (China) Limited - Mentions: LSE -

HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China

7 months ago - By: HUTCHMED (China) Limited

HUTCHMED CHINA-ADR (HCM) Stock News

HCM Latest News, Press Relases and Analysis

HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2025

HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2025

IBEX, Tesla, IonQ, Warner Bros. Discovery And Other Big Stocks Moving Higher On Friday

Save the Date: HUTCHMED to Present R&D Updates on October 31, 2025

Best Momentum Stock to Buy for August 19th

Earnings Scheduled For August 7, 2025

Save the Date: HUTCHMED to Present R&D Updates on October 31, 2025

HUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer and the CSCO Annual Meeting 2025

HUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer and the CSCO Annual Meeting 2025

HUTCHMED Announces Appointment of Acting Chief Executive Officer

HUTCHMED Announces Appointment of Acting Chief Executive Officer

HUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China

HUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China

HUTCHMED Reports 2025 Interim Results

HUTCHMED to Announce 2025 Half-Year Financial Results

HUTCHMED to Announce 2025 Half-Year Financial Results

HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor Therapy

HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor Therapy

Wall Street Analysts See a 68.3% Upside in HUTCHMED (HCM): Can the Stock Really Move This High?

Hutchmed Stock Hits Over One-Month High After China Accepts Kidney Cancer NDA Filed With Partner Innovent Biologics

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma

HUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual Meeting

HUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual Meeting

HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting

HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting

Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing

UPDATE - International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 15, 2025

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 15, 2025

HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025

HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025

HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China

HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China

HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma